CLINICAL TRIALS PROFILE FOR AVAPRO

All Clinical Trials for AVAPRO

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00095290 ↗	Irbesartan Versus Placebo in Combination With Ramipril for Treatment of Albuminuria	Completed	Sanofi	Phase 4	2004-09-01	Albumin in the urine is usually a signal that you might be at risk of cardiovascular complications. The purpose of this study is to determine if the albumin in your urine can be decreased by the treatment regimen that consists of irbesartan taken at the same time with ramipril.
NCT00095290 ↗	Irbesartan Versus Placebo in Combination With Ramipril for Treatment of Albuminuria	Completed	Bristol-Myers Squibb	Phase 4	2004-09-01	Albumin in the urine is usually a signal that you might be at risk of cardiovascular complications. The purpose of this study is to determine if the albumin in your urine can be decreased by the treatment regimen that consists of irbesartan taken at the same time with ramipril.
NCT00095394 ↗	Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy as First Line Treatment for Severe Hypertension	Completed	Sanofi	Phase 3	2004-09-01	The purpose of this clinical research is to learn if severe hypertension can be better controlled by initially treating with a combination of drugs (Irbesartan/HCTZ), in patients who are unlikely to achieve blood pressure (B/P) control with only one drug. In addition, the study will also evaluate the safety and tolerability of the drugs.
NCT00095394 ↗	Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy as First Line Treatment for Severe Hypertension	Completed	Bristol-Myers Squibb	Phase 3	2004-09-01	The purpose of this clinical research is to learn if severe hypertension can be better controlled by initially treating with a combination of drugs (Irbesartan/HCTZ), in patients who are unlikely to achieve blood pressure (B/P) control with only one drug. In addition, the study will also evaluate the safety and tolerability of the drugs.
NCT00095550 ↗	Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy for Patients With Moderate Hypertension	Completed	Sanofi	Phase 3	2004-10-01	The purpose of this clinical research is to learn if moderate hypertension can be better controlled by initially treating with a combination of drugs (Irbesartan/HCTZ), in patients who are unlikely to achieve blood pressure (B/P) control with only one drug. In addition, the study will also evaluate the safety and tolerability of the drugs.
NCT00095550 ↗	Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy for Patients With Moderate Hypertension	Completed	Bristol-Myers Squibb	Phase 3	2004-10-01	The purpose of this clinical research is to learn if moderate hypertension can be better controlled by initially treating with a combination of drugs (Irbesartan/HCTZ), in patients who are unlikely to achieve blood pressure (B/P) control with only one drug. In addition, the study will also evaluate the safety and tolerability of the drugs.

Clinical Trial Conditions for AVAPRO

Condition Name

Condition Name for AVAPRO
Intervention	Trials
Hypertension	7
Kidney Failure, Chronic	1
Kidney Transplantation	1
Metabolic Syndrome	1

Condition MeSH

Condition MeSH for AVAPRO
Intervention	Trials
Hypertension	5
Atrial Fibrillation	2
Virus Diseases	1
Syndrome	1

Clinical Trial Locations for AVAPRO

Trials by Country

Trials by Country for AVAPRO
Location	Trials
United States	123
Canada	31
Germany	8
Mexico	5
Australia	4

Trials by US State

Trials by US State for AVAPRO
Location	Trials
Texas	7
Wisconsin	5
Pennsylvania	5
Ohio	5
Illinois	5

Clinical Trial Progress for AVAPRO

Clinical Trial Phase

Clinical Trial Phase for AVAPRO
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	5
Phase 2	3

Clinical Trial Status

Clinical Trial Status for AVAPRO
Clinical Trial Phase	Trials
Completed	10
Unknown status	3
Active, not recruiting	1

Clinical Trial Sponsors for AVAPRO

Sponsor Name

Sponsor Name for AVAPRO
Sponsor	Trials
Sanofi	6
Bristol-Myers Squibb	5
Roxane Laboratories	2

Sponsor Type

Sponsor Type for AVAPRO
Sponsor	Trials
Industry	19
Other	9